Trial Profile
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 16 Jul 2019 Results (n=14) assessing efficacy, focusing on clinical picture and metabolic profile, and details the safety management of pasireotide treatment published in the Journal of Endocrinological Investigation
- 27 May 2014 New trial record